New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
09:03 EDTICPTIntercept thesis unchanged with pushed out data, says Summer Street
Summer Street said it sees no reason to change its thesis on shares of Intercept after the company said the FLINT data is likely to be released in August, from July previously. The firm believes the data could represent a "significant positive catalyst" for the stock, and it thinks the potential for breakthrough designation on positive data remains a "very real possibility." Summer Street reiterates a Buy rating on Intercept with a $650 price target.
News For ICPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2015
05:44 EDTICPTIntercept FLINT trial data shows OCA treatment increases fibrosis resolution
Subscribe for More Information
April 22, 2015
07:07 EDTICPTEuropean Association for the Study of the Liver to hold annual meeting
50th Annual Meeting of EASL will be held in Vienna, Austria on April 22-26.
April 17, 2015
10:00 EDTICPTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:53 EDTICPTIntercept initiated with a Buy, $465 target at UBS
UBS analyst Matthew Roden started shares of Intercept Pharmaceuticals with a Buy rating and $465 price target. Roden sees a favorable risk/reward ahead of the approval and commercial launch of the company's obeticholic acid, known as OCA, in primary biliary cirrhosis. Roden also thinks OCA's opportunity in nonalcoholic steatohepatitis is being undervalued at current share levels. Shares of Intercept closed yesterday up $2.53 to $274.44.
April 13, 2015
08:24 EDTICPTDeutsche Bank pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
06:07 EDTICPTIntercept announces several presentations evaluating OCA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use